Media

Invitation to conference call for updated results from the LYMRIT 37-01 Phase 1/2 trial, to be presented at ASH

GenSight Biologics reports positive long-term visual acuity gains and safety results from Phase I/II Study of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)

Nordic Nanovector to Present at Carnegie Nordic Healthcare day

Nexstim Plc Appoints Steve Beller as Vice President and General Manager, North America

Orexo publishes prospectus and applies for listing of bonds on Nasdaq Stockholm

Onxeo Establishes Scientific Advisory Board with International Experts in DNA-targeting

Wilson Therapeutics AB (publ) Interim Report January 1–September 30, 2017

First patients enter TARGET study, recently initiated by Cerenis Therapeutics to evaluate HDL nanoparticles in patients with esophageal cancer

Nordic Nanovector Capital Markets Day 2017